1. Elevated Serum Liver-Type Fatty Acid Binding Protein Levels in Non-acetaminophen Acute Liver Failure Patients with Organ Dysfunction
- Author
-
Jaime L. Speiser, William M. Lee, Mélanie Tremblay, Constantine J. Karvellas, Christopher F. Rose, and Université de Montréal. Faculté de médecine. Département de médecine
- Subjects
medicine.medical_specialty ,Physiology ,medicine.medical_treatment ,Autoimmune hepatitis ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Severity of illness ,medicine ,Renal replacement therapy ,Hepatic encephalopathy ,business.industry ,ALFSG index ,digestive, oral, and skin physiology ,Organ dysfunction ,Hepatitis B ,Hepatology ,Prognosis ,medicine.disease ,Acetaminophen ,Liver-type fatty acid binding protein ,Multiorgan failure ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Acute liver failure ,medicine.drug - Abstract
Liver-type fatty acid binding protein (FABP1) has previously been demonstrated to improve prognostic discrimination in acetaminophen (APAP)-induced ALF but has not been investigated in other etiologies of ALF. AIM: To determine whether FABP1 levels (early: admission or late: days 3-5) are associated with 21-day transplant-free survival in non-APAP ALF. METHODS: FABP1 was measured in serum samples from 384 ALF patients (n = 88 transplant-free survivors (TFS), n = 296 died/LT-NTFS) using solid-phase enzyme-linked immunosorbent assay and analyzed with US ALFSG registry data. RESULTS: Of 384 ALF patients (autoimmune hepatitis n = 125, drug-induced liver injury n = 141, Hepatitis B n = 118), 177 (46%) patients received LT. Early FABP1 levels were significantly higher in ALF patients requiring vasopressor support (203.4 vs. 76.3 ng/mL) and renal replacement therapy (203.4 vs. 78.8 ng/mL; p
- Published
- 2020